News & Events
Read the latest news and event updates from Ariceum
© Ariceum Therapeutics
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer
Berlin, Germany, 7th September 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce that the first patient has been dosed with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC), at the GenesisCare Murdoch Theranostics and Molecular Imaging Centre in Perth, Australia.
Ariceum Therapeutics and Eurofins CDMO Sign a Pharmaceutical Multi-Project Agreement
Berlin, Germany, and Nantes, France, 26 June 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eurofins CDMO (part of Eurofins’ network of companies – Eurofins Scientific SE (EURONEXT PARIS: ERF)), a leading global Contract Development and Manufacturing Organization, today announce a strategic partnership which will see Eurofins CDMO provide Clinical Trial Supply services to support Ariceum’s current Phase I/II clinical studies in Australia, as well as future clinical studies.
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
Berlin, Germany, 1 June 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the acquisition of Theragnostics Ltd., a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours.
UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer
Berlin, Germany, and Brussels, Belgium, 11 May 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers,and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced an exclusive, strategic research collaboration agreement to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.
UCB und Ariceum Therapeutics unterzeichnen strategische Forschungskooperation zur Entdeckung neuer Modalitäten für die Behandlung von Immunerkrankungen und Krebs
BERLIN und BRÜSSEL, 11. Mai 2023 – Ariceum Therapeutics (Ariceum), ein privates Biotech-Unternehmen, das radiopharmazeutische Produkte für die Diagnose und Behandlung bestimmter schwer behandelbarer Krebsarten entwickelt, und UCB (EURONEXT BRUSSELS: UCB), ein weltweit tätiges biopharmazeutisches Unternehmen, gaben heute eine exklusive, strategische Forschungskooperation zur Identifizierung und Entwicklung neuartiger systemischer, zielgerichteter Radiopharmazeutika für die Behandlung solider Tumore und Immunerkrankungen bekannt.
Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline
New investors, Andera Partners and Earlybird Venture Capital, join existing investor, Pureos Bioventures raising an additional EUR 22.75 million Funds will be used to advance clinical pipeline and further build Ariceum Therapeutics Olivier Litzka from Andera Partners and Christoph Massner from Earlybird Venture Capital to join the Ariceum non-executive Board of Directors Berlin, Germany, 18 […]